⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1569461 | 0.97 | — | — | |
| SCHEMBL19358647 | 0.89 | — | — | |
| SCHEMBL3962371 | 0.86 | — | — | |
| SCHEMBL15546403 | 0.85 | — | — | |
| SCHEMBL13385702 | 0.74 | — | — | |
| SCHEMBL20291506 | 0.74 | — | — | |
| SCHEMBL21591085 | 0.72 | SIGMAR1 (0.30) | — | |
| SCHEMBL1303719 | 0.71 | — | — | |
| SCHEMBL16035833 | 0.70 | — | — | |
| SCHEMBL19358644 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 527 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199581-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | C4 THERAPEUTICS, INC. (US) | 2024-06-20 | — | — | US | claimed |
| EP-4351583-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | C4 Therapeutics, Inc. (US) | 2024-04-17 | — | — | EP | claimed |
| US-11690848-B2 | Alkoxy pyrazoles as soluble guanylate cyclase activators | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-07-04 | — | — | US | claimed |
| WO-2023122581-A2 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2023-06-29 | — | — | WO | claimed |
| WO-2022261250-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | C4 THERAPEUTICS, INC. (US) | 2022-12-15 | — | — | WO | claimed |
| EP-3820470-A1 | ALKOXY PYRAZOLES AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | Boehringer Ingelheim International GmbH (DE) | 2021-05-19 | — | — | EP | claimed |
| US-20210121473-A1 | Alkoxy Pyrazoles as Soluble Guanylate Cyclase Activators | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-04-29 | — | — | US | claimed |
| WO-2020011804-A1 | ALKOXY PYRAZOLES AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-01-16 | — | — | WO | claimed |
| EP-2892891-B1 | ALKOXY PYRAZOLES AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | BOEHRINGER INGELHEIM INT (DE) | 2019-07-31 | — | — | EP | claimed |
| EP-3470396-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2019-04-17 | — | — | EP | claimed |
| US-20140073629-A1 | ALKOXY PYRAZOLES AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-03-13 | — | — | US | claimed |
| WO-2014039434-A1 | ALKOXY PYRAZOLES AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-03-13 | — | — | WO | claimed |
| EP-2697198-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2014-02-19 | — | — | EP | claimed |
| WO-2013027001-A1 | COMPOUNDS AND THEIR USE TO TREAT HISTAMINE H3 RELATED DISORDERS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-02-28 | — | — | WO | claimed |
| WO-2012142513-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2012-10-18 | — | — | WO | claimed |
| US-8268827-B2 | Pyridazinone derivatives as PARP inhibitors | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA. (IT) | 2012-09-18 | — | — | US | claimed |
| US-20100261709-A1 | PYRIDAZINONE DERIVATIVES AS PARP INHIBITORS | MSD ITALIA S.R.L. (IT) | 2010-10-14 | — | — | US | claimed |
| EP-2220073-A1 | PYRIDAZINONE DERIVATIVES AS PARP INHIBITORS | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. (IT) | 2010-08-25 | — | — | EP | claimed |
| WO-2009063244-A1 | PYRIDAZINONE DERIVATIVES AS PARP INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2009-05-22 | — | — | WO | claimed |
| US-7361668-B2 | Quinuclidine derivatives processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors | UCB, S.A. (BE) | 2008-04-22 | — | — | US | claimed |